AGIO
Price
$36.07
Change
+$0.72 (+2.04%)
Updated
Jul 3 closing price
Capitalization
2.09B
27 days until earnings call
LGND
Price
$114.58
Change
+$0.92 (+0.81%)
Updated
Jul 3 closing price
Capitalization
2.21B
38 days until earnings call
Interact to see
Advertisement

AGIO vs LGND

Header iconAGIO vs LGND Comparison
Open Charts AGIO vs LGNDBanner chart's image
Agios Pharmaceuticals
Price$36.07
Change+$0.72 (+2.04%)
Volume$258.71K
Capitalization2.09B
Ligand Pharmaceuticals
Price$114.58
Change+$0.92 (+0.81%)
Volume$52.06K
Capitalization2.21B
AGIO vs LGND Comparison Chart in %
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. LGND commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a StrongBuy and LGND is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (AGIO: $36.07 vs. LGND: $114.58)
Brand notoriety: AGIO and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 46% vs. LGND: 42%
Market capitalization -- AGIO: $2.09B vs. LGND: $2.21B
AGIO [@Biotechnology] is valued at $2.09B. LGND’s [@Biotechnology] market capitalization is $2.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than LGND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 3 TA indicator(s) are bullish while LGND’s TA Score has 4 bullish TA indicator(s).

  • AGIO’s TA Score: 3 bullish, 5 bearish.
  • LGND’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both AGIO and LGND are a bad buy in the short-term.

Price Growth

AGIO (@Biotechnology) experienced а +7.19% price change this week, while LGND (@Biotechnology) price change was -0.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

AGIO is expected to report earnings on Jul 31, 2025.

LGND is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LGND($2.21B) has a higher market cap than AGIO($2.09B). LGND has higher P/E ratio than AGIO: LGND (46.19) vs AGIO (3.13). AGIO YTD gains are higher at: 9.769 vs. LGND (6.934). LGND has higher annual earnings (EBITDA): -122.1M vs. AGIO (-434.71M). AGIO has more cash in the bank: 893M vs. LGND (209M). LGND has less debt than AGIO: LGND (4.45M) vs AGIO (52.9M). LGND has higher revenues than AGIO: LGND (181M) vs AGIO (37M).
AGIOLGNDAGIO / LGND
Capitalization2.09B2.21B94%
EBITDA-434.71M-122.1M356%
Gain YTD9.7696.934141%
P/E Ratio3.1346.197%
Revenue37M181M20%
Total Cash893M209M427%
Total Debt52.9M4.45M1,189%
FUNDAMENTALS RATINGS
AGIO vs LGND: Fundamental Ratings
AGIO
LGND
OUTLOOK RATING
1..100
6569
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
1793
PRICE GROWTH RATING
1..100
4746
P/E GROWTH RATING
1..100
7993
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (41) in the Biotechnology industry is somewhat better than the same rating for LGND (75). This means that AGIO’s stock grew somewhat faster than LGND’s over the last 12 months.

LGND's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for AGIO (100). This means that LGND’s stock grew somewhat faster than AGIO’s over the last 12 months.

AGIO's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for LGND (93). This means that AGIO’s stock grew significantly faster than LGND’s over the last 12 months.

LGND's Price Growth Rating (46) in the Biotechnology industry is in the same range as AGIO (47). This means that LGND’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's P/E Growth Rating (79) in the Biotechnology industry is in the same range as LGND (93). This means that AGIO’s stock grew similarly to LGND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOLGND
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 5 days ago
76%
Bearish Trend 4 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGIKX68.62N/A
N/A
Fidelity Growth & Income K
FAMEX59.64N/A
N/A
FAM Dividend Focus Fund Investor
PAARX16.56N/A
N/A
Putnam Dynamic Asset Allocation Bal R
MMVYX9.44N/A
N/A
MassMutual Small Company Val Svc
RMBTX11.20N/A
N/A
RMB International I

LGND and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with SYRE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
+0.81%
SYRE - LGND
51%
Loosely correlated
+1.68%
AGIO - LGND
51%
Loosely correlated
+2.04%
ACLX - LGND
49%
Loosely correlated
+1.24%
AXON - LGND
49%
Loosely correlated
+2.70%
CRSP - LGND
48%
Loosely correlated
+0.97%
More